We are live on ! Find out more
XBIT icon

XBiotech

48 hedge funds and large institutions have $59.3M invested in XBiotech in 2017 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

69% more capital invested

Capital invested by funds: $35.1M → $59.3M (+$24.2M)

0% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 16

0.46% less ownership

Funds ownership: 10.69%10.23% (-0.46%)

2% less funds holding

Funds holding: 4948 (-1)

12% less call options, than puts

Call options by funds: $2.9M | Put options by funds: $3.29M

Holders
48
Holders Change
-1
Holders Change %
-2.04%
% of All Funds
1.19%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
9
Increased
16
Reduced
16
Closed
5
Calls
$2.9M
Puts
$3.29M
Net Calls
-$397K
Net Calls Change
+$30K
Name Holding Trade Value Shares
Change
Change in
Stake
Group One Trading
51
Group One Trading
Illinois
-$29.8K -2,279 Closed
TRCT
52
Tower Research Capital (TRC)
New York
-$6K -610 Closed
AIM
53
Acrospire Investment Management
Illinois
-$2K -200 Closed

XBIT Hedge Fund Activity: Q1 2017 in Review

48 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2017, worth a combined $59.3M — up 69% from $35.1M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new XBIT positions and 5 closed out — a net gain of 4 holders — while 16 added to existing stakes and 16 trimmed.

The largest buyer was BlackRock, adding an estimated $16.9M. The largest seller was Susquehanna International Group, cutting an estimated $494K.

  • 48 institutional investors held XBiotech (XBIT) as of Q1 2017, down from 49 in Q4 2016.
  • Funds reported $59.3M of XBiotech stock for Q1 2017, up 69% quarter-over-quarter.
  • 9 funds opened new XBiotech positions in Q1 2017 and 5 closed out, a net change of +4 holders.
  • The largest XBiotech buyer in Q1 2017 was BlackRock, an estimated $16.9M added.
  • The largest XBiotech seller in Q1 2017 was Susquehanna International Group, an estimated $494K sold.

Based on aggregated 13F filings for Q1 2017.